A.W.A.R.E.-2

About this trial

Last updated 12 years ago

Study ID

A.W.A.R.E.-2

Status

Terminated

Type

Observational

Placebo

Accepting

18+ Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended 15 years ago

The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.

Inclusion Criteria

- Subjects with moderate to severe chronic plaque psoriasis who receive a new prescription for alefacept

Exclusion Criteria

- Subjects with a contraindication to alefacept

- Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions)

- Subjects with any active cancer, including skin cancer

- Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept.

- Subjects known to be infected with the AIDS virus

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis